BIB_396
Tan SX, Muller NM, Zhou C (Univ Queensland / Princess Alexandra Hospital, 2024 JAAD Int) — Modeling study: existing prognostic markers can identify Stage IB/IIA melanoma patients with predicted 5-yr MSS ≤83% (Stage IIIB–comparable risk). DIRECTLY addresses the brief's "why no adjuvant at Stage IB" conceptual gap and provides the theoretical basis for the NivoMela Phase III trial (NCT04309409, Stage IIA–IIC, MelaGenix GEP-selected). NOT a recommendation change at current Stage IB; fills STATE.md open unknown: "which biomarker signals would push Stage IB toward adjuvant-trial eligibility?"
- Evidence grade
- C
- Tier
- 2 (JAAD Int, peer-reviewed open-access journal; modelin
- Cited by tasks
- 5a, 15, 17, 18
- Identifiers
- PMC11617983 · DOI:10.1016/j
↗ Follow the original source for full context
Full extracted findings & patient-implication analysis: bibliography/BIB_396/findings.md (research corpus). This page is a short context summary — not individualised medical advice.